CD13 identifies S100A4(+) immunosuppressive monocytes and predicts temozolomide benefit in glioblastoma.
A surface marker on immune-suppressing cells predicts which brain tumor patients benefit from standard chemotherapy, enabling smarter treatment selection.
This study used multi-platform genomic datasets (TCGA, Human Protein Atlas, scRNA-seq) to identify CD13 as the key surface marker on immunosuppressive monocytes in glioblastoma, positioned in a CD13-TGFβ-S100A4 immunosuppressive axis. Critically, CD13-high expression predicted selective survival benefit from temozolomide—the standard GBM chemotherapy—suggesting CD13 could serve as a precision biomarker to stratify patients for chemotherapy vs. alternative approaches.
What the study was
- Study design
- bioinformatics_retrospective
- Population
- Glioblastoma multiforme patients and GBM cell datasets
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Biol Direct
Why it surfaced
Identifies CD13 as a novel predictive biomarker for temozolomide response in GBM, which has almost universally poor prognosis and urgent need for treatment personalization; CD13 is a surface-accessible target; multi-dataset validation provides preliminary confidence for clinical translation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.